Physician profile
Joseph Peter Evers
NPI 1649233289
$2,145.36
in general payments reported to CMS, 2019-2025
37 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.29 · 2021: $33.26 · 2022: $348 · 2023: $384 · 2024: $502 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $271.12 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $215.21 | 2021-2025 | Lynparza, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $159.42 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Incyte Corporation | $140.54 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Biotech, INC. | $110.62 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Pfizer INC. | $103.05 | 2022-2025 | |
| Eisai INC. | $95.98 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $78.43 | 2022-2025 | Onivyde, Somatuline Depot |
| E.R. Squibb & Sons, L.L.C. | $78.25 | 2022-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $71.59 | 2022 | |
| Daiichi Sankyo INC. | $67.29 | 2022-2025 | Injectafer, Enhertu |
| Genentech USA, INC. | $64.00 | 2023-2025 | Tecentriq, Alecensa, Rozlytrek |
| Regeneron Healthcare Solutions, INC. | $63.92 | 2022-2024 | Libtayo |
| Beone Medicines USA, INC. | $60.17 | 2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $49.20 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $44.29 | 2022-2023 | Imbruvica, Epkinly |
| Teva Pharmaceuticals USA, INC. | $42.60 | 2022 | |
| Pharmacosmos Therapeutics INC. | $38.64 | 2023-2025 | Monoferric |
| Genzyme Corporation | $38.20 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.74 | 2025 | Iclusig |
| Astellas Pharma US INC | $34.59 | 2023 | Xtandi, Xospata |
| Deciphera Pharmaceuticals INC. | $27.42 | 2025 | Qinlock, Romvimza |
| Kite Pharma, INC. | $25.02 | 2023 | Yescarta |
| Beigene USA, INC. | $23.05 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $20.35 | 2024 | Ultomiris |
| Array Biopharma INC | $19.17 | 2024 | Braftovi, Lorbrena, Mektovi |
| Puma Biotechnology, INC. | $18.74 | 2022 | |
| Amgen INC. | $18.43 | 2023 | Nplate, Vectibix, Xgeva |
| Stemline Therapeutics INC. | $16.75 | 2024 | Orserdu |
| Genmab U.S., INC. | $15.42 | 2025 | Epkinly |
| Tersera Therapeutics LLC | $14.88 | 2024 | Zoladex |
| Apellis Pharmaceuticals, INC. | $14.83 | 2022 | |
| Adc Therapeutics America, INC. | $14.34 | 2024 | |
| Caris Mpi, INC. | $14.32 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $13.58 | 2023 | Pomalyst |
| Seagen INC. | $12.29 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Evers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.